2. UroToday Home
  3. Video Lectures

PSMA Targeted Therapy

ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
October 30, 2024
Details
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
October 2, 2024
Details
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
October 1, 2024
Details
Exploring Actinium-225: Transforming Cancer Treatment with Targeted Radiopharmaceuticals - John Valliant
September 3, 2024
Details
Dose-Escalation of Lutetium PSMA: Final Results from a Phase I/II Trial - Scott Tagawa
June 13, 2024
Details
Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman
May 31, 2024
Details
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
May 24, 2024
Details
Patient Selection for Radioligand Therapy: Case Study Discussion - Amir Iravani & Evan Yu
April 11, 2024
Details
Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team - Kristen Davis & Sarah Yenser Wood
March 20, 2024
Details
Patient Selection for PSMA Radioligand Therapy - Ephraim Parent
February 7, 2024
Details
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor
February 2, 2024
Details
Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor
February 2, 2024
Details
Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais
January 30, 2024
Details
ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett
November 20, 2023
Details
LuTectomy Study Shows Promise: Targeted Radiation Safe Before Prostate Cancer Surgery - Michael Hofman & Renu Eapen
November 13, 2023
Details
The Evolution of PSMA Theranostics: A 30-Year Journey with the Prostate Cancer Foundation - Andrea Miyahira
November 2, 2023
Details
PSMA PET and Radioligand Therapy: A Comprehensive Two-Day Conference by UCLA and UCSF - Jeremie Calais & Thomas Hope
October 11, 2023
Details
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy - Thomas Hope
September 25, 2023
Details
The Radiopharmaceutical Revolution: New Frontiers in Prostate Cancer Treatment - Oliver Sartor
July 5, 2023
Details
From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi
June 16, 2023
Details
PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong
April 21, 2023
Details
Exploring the Potential of Lutetium PSMA in High-Risk Localized Prostate Cancer: The LuTectomy Trial - Renu Eapen
November 23, 2022
Details
Exploring the New Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans
November 22, 2022
Details
The Implementation of PSMA Theranostics in Clinical Practice - Oliver Sartor
July 19, 2022
Details
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
June 16, 2022
Details
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
April 3, 2022
Details
Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor
March 28, 2022
Details
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
March 10, 2022
Details
Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo
December 16, 2021
Details
Ongoing Clinical Trials Evaluating The Efficacy of Targeted Radioligand Therapy - Shahneen Sandhu
November 29, 2021
Details
The Use of Imaging for Patient Selection for PSMA Directed Therapies – Jeremie Calais
November 4, 2021
Details
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
October 15, 2021
Details
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
October 3, 2021
Details
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
August 12, 2021
Details
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
July 20, 2021
Details
Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor
June 23, 2021
Details
PSMAddition, the Integration of Lutetium-177 With the Standard of Care Therapy in Metastatic Castrate-Sensitive Prostate Cancer Patients – Scott Tagawa & Oliver Sartor
June 18, 2021
Details
The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor
June 7, 2021
Details
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
June 4, 2021
Details
177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman
March 22, 2021
Details
Targeted Radionuclide Therapy of Prostate Cancer - Wolfgang Weber
June 21, 2020
Details
TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Michael Hofman & Ian Davis
May 29, 2020
Details
TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer - Michael Hofman
May 8, 2020
Details
Targeted Molecular Therapies for Treatment of Advanced Prostate Cancer - Scott Tagawa
March 30, 2020
Details
The Evolving Role of Lutetium-PSMA in the Era of Personalized Medicine - Michael Hofman
March 30, 2020
Details
Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni
January 8, 2020
Details
Outcomes of Patients From PSMA Targeted Radionuclide Trials - Panagiotis Vlachostergios
August 8, 2020
Details
High Activity Pain Reduction and Low Toxicity with Lu177 PSMA617 Theranostics - Michael Hofman
December 27, 2019
Details
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
November 18, 2019
Details
177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor
October 31, 2019
Details
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor
October 14, 2019
Details
PSMA Targeted Therapies Presentation - Michael Hofman
September 18, 2019
Details
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
February 25, 2019
Details
Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais
February 4, 2019
Details